AG真人官方

Immunome, Inc. (IMNM) 鈥� Form 4 insider filing

Chief Technical Officer Philip Tsai was granted an employee stock option for 190,000 common shares on 29-Jul-2025 at an exercise price of $10.60. The options expire on 28-Jul-2035. No common shares were bought, sold or otherwise transferred in the filing; the entire award is reported as directly owned.

Vesting schedule: 25 % of the grant vests on 29-Jul-2026; the remaining 75 % vests in 36 equal monthly installments thereafter. Following this grant, Tsai beneficially owns 190,000 derivative securities (options) and no change to his non-derivative share count is disclosed.

The transaction is a routine equity incentive meant to align executive interests with shareholders. Dilution will only occur if the options are exercised at prices above $10.60.

Immunome Inc. (IMNM) filed a Form 4 for Chief Medical Officer Dr. Robert Lechleider, reporting the grant of 242,000 employee stock options on 07/29/2025. The options carry a $10.60 exercise price and expire on 07/28/2035. Vesting terms: 25 % on 07/29/2026, then monthly vesting of the remaining 75 % over 36 months, leading to full vesting by 07/29/2029. After the award, the CMO beneficially owns 242,000 derivative securities; no common-stock holdings or open-market trades were disclosed. The transaction is coded 鈥淎鈥� (grant) and is held directly; no 10b5-1 plan was indicated. The filing represents standard incentive compensation with no immediate share dilution or cash impact for investors.

Form 4 filing 鈥� Immunome, Inc. (IMNM) discloses that Chief Business Officer Kinney Horn received a new employee stock-option grant for 161,000 shares on 07/29/2025.

• Instrument: Non-qualified employee stock option giving the right to buy common stock at an exercise price of $10.60 per share.
• Vesting: 25 % vests on 07/29/2026; the remaining 75 % vests in equal monthly installments (1鈦�36) thereafter, fully vesting by 07/29/2029.
• Expiration: 07/28/2035 (10-year term).
• Post-grant holdings: Horn now beneficially owns 161,000 derivative securities; no common shares were reported in Table I.

No shares were sold or disposed of, so the filing reflects compensation-related equity issuance rather than insider selling. The grant modestly increases the company鈥檚 fully-diluted share count and aligns the officer鈥檚 incentives with long-term shareholder value.

Form 4 snapshot: On 07/29/2025 Immunome (IMNM) granted Chief Scientific Officer Jack Higgins an employee stock option for 196,000 common shares at a strike price of $10.60. The option expires on 07/28/2035, giving a standard 10-year term.

Vesting schedule: 25 % of the award vests on 07/29/2026; the remaining 75 % vests in equal monthly installments over the next 36 months, completing vesting by mid-2029.

Table I shows no purchases or sales of non-derivative shares, so Higgins鈥� direct common-stock position is unchanged. After the grant he beneficially owns 196,000 derivative securities, all held directly.

Investor takeaway: The filing records routine executive compensation; no immediate cash outlay occurred and potential dilution is limited to the new option pool.